RGD-Modified Angiogenesis Inhibitor HM-3 Dose: Dual Function during Cancer Treatment
Author:
Affiliation:
1. State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, P. R. China
2. Department of Oral Pathology, Nanjing Stamotology Hospital, Affiliated Medical School, Nanjing University, 210008, P. R. China
Publisher
American Chemical Society (ACS)
Subject
Organic Chemistry,Pharmaceutical Science,Pharmacology,Biomedical Engineering,Bioengineering,Biotechnology
Link
https://pubs.acs.org/doi/pdf/10.1021/bc2000929
Reference12 articles.
1. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
2. Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
3. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
4. Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma
5. Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Cited by 22 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Research progress on the interaction between oxidative stress and platelets: Another avenue for cancer?;Pharmacological Research;2023-05
2. HM-3-HSA exhibits potent anti-angiogenesis and antitumor activity in hepatocellular carcinoma;European Journal of Pharmaceutical Sciences;2021-12
3. Integrins as attractive targets for cancer therapeutics;Acta Pharmaceutica Sinica B;2021-09
4. Albumin Fusion at the N-Terminus or C-Terminus of HM-3 Leads to Improved Pharmacokinetics and Bioactivities;Biomedicines;2021-08-25
5. Review and comparative analysis of machine learning-based predictors for predicting and analyzing of anti-angiogenic peptides;Current Medicinal Chemistry;2021-08-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3